Effect of Shadbindu Taila and Haridra Khanda in Pratishyaya (Allergic Rhinitis)

The Healer ◽  
2021 ◽  
Vol 2 (1) ◽  
pp. 58-60
Author(s):  
Sadhana Parajuli ◽  
Pramod Bhatta ◽  
D.L Bharkher
Keyword(s):  
Immune Response ◽  
Allergic Rhinitis ◽  
Nasal Mucosa ◽  
Significant Role ◽  
Vital Sign ◽  
Nasal Congestion ◽  
Combined Therapy ◽  
Nasal Discharge ◽  
Before And After ◽  
Airborne Allergens

Allergic rhinitis (AR) is an immune response of the nasal mucosa to airborne allergens and involves nasal congestion, watery nasal discharge, itching of the nose, and sneezing. Ayurveda describes Pratishyaya as one of the most important diseases among the 31 Nasarogas. Acharya Sushruta clearly mentioned that Pratishyaya is the condition in which vata kapha dusti was observed. Haridra Khanda is one of the prominent anti allergic drugs mentioned in ayurveda. Pratimarsha nasya has significant role in the prevention of urdhvajatrugata rogas. Ancient acharya has told to try shadbindu taila and Haridra khanda both locally and systematically in the management of pratishyaya. Here 30 patients were selected open randomly in shalakya opd of ayurveda campus kirtipur. They were given pratimarsha nasya with sadhbindu taila and internally haridra khanda for 30 days. The vital sign and symptom of pratishyaya like nasa srava, nasa kandu, kshavatu, nasa kandu and shira shula were studied before and after the treatment. The result of the study indicated that the combined therapy of internally Haridra Khanda and external pratimarsha narsha with sadbindu tail has given significant result in the treatment of Allergic Rhinitis (Pratishyaya).

Pharmacoeconomic features of the use of drugs used in the treatment of allergic rhinitis

2021 ◽  
pp. 9-16
Author(s):  
Afanasyeva T.G. ◽  
Lavrova N.N. ◽  
Tumentseva V.R.
Keyword(s):  
Quality Of Life ◽  
Allergic Rhinitis ◽  
Nasal Mucosa ◽  
Generic Drugs ◽  
Cost Minimization ◽  
Nasal Congestion ◽  
World Health ◽  
Cost Minimization Analysis ◽  
Wide Range

Rhinitis is an inflammation of the nasal mucosa; today, according to the World Health Organization, the prevalence of the disease is 40% of the world's population. Allergic rhinitis is the most common type of chronic rhinitis, affecting 10–20% of the world's population, and the severity of the disease is associated with a significant deterioration in the quality of life, sleep and performance. Allergic rhinitis is an inflammatory disease of the nasal mucosa caused by exposure to an allergen, causing IgE-mediated inflammation. Clinically, the disease is characterized by the following main symptoms: rhinorrhea, sneezing, itching and nasal congestion. Despite the general symptoms of allergic rhinitis, its impact on the quality of life of patients and the significant cost of treatment, including pharmacotherapy, many patients do not adhere to drug treatment regimens due to their insufficient effectiveness in eliminating the emerging symptoms. Pharmacoeconomic research identifies, measures and compares the costs and effects of drug use. This framework includes research methods related to cost minimization, cost-effectiveness, decision analysis, cost of illness, and patient quality of life. This article will consider one of the four main methods for assessing pharmacoeconomics - cost minimization analysis. A cost-minimization analysis is a pharmacoeconomic assessment by comparing the costs of two or more drug alternatives regardless of outcome. Since the pharmaceutical market is represented by a wide range of original, reference and generic drugs for the treatment of allergic rhinitis, an important aspect of our research is the selection of effective and economically acceptable therapy for outpatients.

Mast cell stabilizers

1992 ◽  
Vol 107 (6_part_2) ◽  
pp. 841-844 ◽  
Author(s):  
Hueston C. King
Keyword(s):  
Allergic Rhinitis ◽  
Mast Cell ◽  
Cell Membrane ◽  
Nasal Mucosa ◽  
Nasal Polyps ◽  
Nasal Congestion ◽  
Correct Diagnosis ◽  
Vasomotor Rhinitis ◽  
Ige Mediated ◽  
Exercise Induced

The precise mode of action of the well-studied cromolyn sodium and the newer nedocromil sodium has not been completely elucidated. Because the drugs do not pass the cell membrane and enter the cell, they are virtually not metabolized, do not exert a systemic action, and therefore are associated with only minimal systemic toxicity. To be effective either drug must be applied topically and directly to the nasal mucosa. Proper contact with the nasal mucosa is essential for efficacy; in patients with nasal congestion and secretions, vasoconstrictors or saline lavages are indicated before cromolyn or nedocromil use. Both products are highly effective in patients who have IgE-mediated allergic rhinitis but must be administered prophylactically before exposure to an allergen to prevent development of the allergic event. Neither drug is effective in vasomotor rhinitis, exercise-induced rhinitis, or in the management of nasal polyps. Correct diagnosis is essential before therapy.

Nasal Responses to Metabisulfite (MBS) Solution in Non-Atopic Subjects and Patients with Atopic Rhinitis

1994 ◽  
Vol 8 (5) ◽  
pp. 231-236 ◽  
Author(s):  
Mariola Śliwińska-Kowalska ◽  
Marek L. Kowalski ◽  
Wiestaw Sutkowski ◽  
Wiktor Wesotowski ◽  
Melvyn R. Danzig
Keyword(s):  
Allergic Rhinitis ◽  
Total Protein ◽  
Clinical Symptoms ◽  
Nasal Congestion ◽  
Absolute Amount ◽  
Protein Ratio ◽  
Nasal Symptoms ◽  
Before And After ◽  
Nasal Secretions ◽  
Dose Dependent Increase

In order to characterize the effect of metabisulfite (MBS) on human nasal mucosa, in 10 healthy, non-atopic subjects and in six patients with atopic rhinitis, 50 mg/mL and 100 mg/mL solutions of MBS were sprayed into both nostrils. Clinical symptoms and Nasal Peak Flow (NPF) were recorded. Nasal lavages were performed before and after MBS challenges. MBS challenge induced similar burning/itching sensation in both groups, but rhinorrhea was significantly more intense (P < 0.02) in atopic patients. There was no nasal congestion and no change in NPF after the challenge. Only in atopic patients were nasal symptoms accompanied by a dose-dependent increase in the concentration of total protein and glandular protein lysozyme in nasal washes (P < 0.05). No statistically significant changes were seen in the absolute amount of plasma protein albumin and albumin to total protein ratio (Albumin %) in nasal secretions. This study demonstrates that MBS induces nasal symptoms both in healthy, non-atopic subjects and in patients with allergic rhinitis; but secretory glandular responses are detected only in patients with allergic rhinitis.

scholarly journals Correlation of Features of Allergic Rhinitis and Allergic Conjunctivitis with Treatment Modalities

2019 ◽  
pp. 1-10 ◽  
Author(s):  
Shuaib Kayode Aremu ◽  
Tayo Ibrahim ◽  
Azeez Oyemomi Ibrahim ◽  
Popoola Tomilayo Ajoke
Keyword(s):  
Allergic Rhinitis ◽  
Allergic Conjunctivitis ◽  
Nasal Congestion ◽  
Nasal Symptom ◽  
Treatment Modalities ◽  
Nasal Discharge ◽  
Southwestern Nigeria ◽  
Cross Sectional ◽  
Female Ratio ◽  
Eye Pain

Introduction: Allergic Rhinitis (AR) is a chronic, symptomatic allergic disorder of the nose that is usually caused by IgE-mediated inflammatory response following exposure to an allergen. The allergen could be in the form of dust, pollen, flower, animal dander, mold, cold, food allergens or insect. Clinically, AR occurs when there are recurrent nasal symptoms which are reversible either spontaneously or with medication in the preceding one year. Such symptoms include at least two of the following; excessive sneezing, running nose, nasal itching, nasal discharge, nasal congestion or obstruction. Previous studies have linked AR to be co-existed with another form of allergic disorders including AC, Atopic dermatitis and Allergic Asthma. This study is aimed at assessing the feature of  AR patients with coexistent AC as well as evaluating the effectiveness of the treatments offered to them. Objectives: The study was aimed at finding the correlation between the nasal and eye features in a patient who has co-existing allergic rhinitis and allergic conjunctivitis. Methodology: This was a cross-sectional descriptive study conducted between August 2018 and November 2019 among 38 patients who presented to ENT and Ophthalmology departments of Federal Teaching Hospital Ido-Ekiti, Ekiti State, Southwestern Nigeria and was diagnosed with both allergic rhinitis and allergic conjunctivitis. Relevant data obtained were analyzed using SPSS version 20.  P ≤ 0.05 was taken as significant. Results: The patients’ age range between 8 and 81 years with a median age of 33 years. The majority were less than 45 years (63.2%) with the male to female ratio of almost. Eye pain, itching, and redness account for 97.4% of all the eye features, while the presence of Cobblestone-like papillae is the least and accounted for 5%. Nasal itching (92.1%) was the commonest nasal symptom. Sleep disturbance was found to be the most common among those with eye itching (29.7%). Conclusion: This research was conducted to correlate the features of allergic rhinitis with those of conjunctivitis and common management and preventive measures offered to the patients seen in our clinics. The majority of the patients were less than 45 years with almost equal sex ratio. Eye pain, itching, and redness account for the majority of all the eye features, while the presence of Cobblestone-like papillae is the least eye feature. Nasal itching was the commonest nasal symptom and this was seen in the majority of the patients with eye symptoms.

The Effects of Probiotic Lactobacillus casei Shirota Strain in Patients with Allergic Rhinitis Symptoms

2015 ◽  
Vol 4 (4) ◽  
pp. 264
Author(s):  
Asti Widuri ◽  
Lilis Suryani
Keyword(s):  
Allergic Rhinitis ◽  
Lactobacillus Casei ◽  
Immunoglobulin E ◽  
Nasal Congestion ◽  
Rank Test ◽  
Inflammatory Reactions ◽  
Runny Nose ◽  
Before And After ◽  
Quasi Experimental ◽  
Signed Rank Test

Allergic rhinitis is inflammatory reactions mediated by immunoglobulin E, after exposure to allergens. The symptoms are sneezing, runny nose and nasal congestion. Allergic rhinitis can be alleviated by the use of specific probiotics selected to confer immune effects, which can be demonstrated in the intestinal tract prior to an allergic reaction. The specific strains used in this study were selected based on their anti-inflammatory properties and an expected effect in promoting a Th1 type of immune response. To review the benefits of probiotics of Lactobacillus casei L Shirota strain in preventing allergy attacks that inhibit the production of IgE, IL-4 and reduce the symptoms. To review the benefits of probiotics of Lactobacillus casei L Shirota strain in preventing allergy attacks that inhibit the production of IgE, IL-4 and reduce the symptoms. The study design was quasi-experimental with pre and post test design. The subject were 45 patients who had a history of allergic rhinitis and positif skin prickt test result and filled out the questionnaires to get the allergic symptoms. The blood samples were taken for examining the IgE and IL-4 levels then after giving milk containing probiotics for 1 month, the researcher did the same examination. The mean IgE and IL-4 levels decrease before and after supplementation probiotics from 291.88 IU / L and 22.48 pg/ml to 141.43 IU / L and 17.83 pg/ml. The result of the statistical analysis paired t-test test was p = 0.00 on IgE level and p=0,056 on IL-4 level. The allergic rhinitis symptoms decreased significantly, the presentage of patients who had persistent and moderate 17.78% to 0% , who had persistent and mild 44.44% to 4.44%, who had intermittent and moderate 13.33% to 2.22%,and who had intermittent and mild 24.44% to 93.33%. Based on the Wilcoxon signed rank test showed a significance value of P = 0.00. Conclusion Probiotics is useful in preventing allergy attacks that inhibit the production of IgE, IL-4 and reduce the symptoms.

scholarly journals New opportunities for the combined therapy of allergic rhinitis in real clinical practice

2019 ◽  
Vol 16 (1) ◽  
pp. 85-89
Author(s):  
E V Nazarova
Keyword(s):  
Allergic Rhinitis ◽  
Clinical Practice ◽  
Nasal Congestion ◽  
Combined Therapy ◽  
Nasal Breathing ◽  
Interferon Alpha 2B ◽  
Eye Symptoms ◽  
Low Incidence ◽  
The Given ◽  
Real Clinical Practice

This paper assesses the efficacy of the original combined medication Allergoferon® beta (betamethasone + interferon alpha-2b) in real clinical practice among patients with seasonal allergic rhinitis (AR). The research program results demonstrated a good efficacy of the given medication: there were a decrease in nasal congestion as well as restoration of nasal breathing and in patients with concomitant allergic conjunctivitis - a reduction in the severity of eye symptoms. A low incidence of side effects was observed. It was shown that Allergoferon® beta can be recommended as monotherapy for patients with mild and moderate AR and in complex therapy for patients with severe AR.

KTP/532 YAG Laser Treatment for Allergic Rhinitis

2009 ◽  
Vol 23 (5) ◽  
pp. 527-530 ◽  
Author(s):  
Eitan Yaniv ◽  
Tuvia Hadar ◽  
Jacob Shvero ◽  
Rami Tamir ◽  
Ben Nageris
Keyword(s):  
Allergic Rhinitis ◽  
Nasal Obstruction ◽  
Nasal Congestion ◽  
Additional Treatment ◽  
Skin Tests ◽  
Nasal Discharge ◽  
Office Procedure ◽  
Positive Skin ◽  
Yag Laser ◽  
Symptom Reports

Background The purpose of this study was to investigate the efficacy of the KTP/532 YAG laser to reduce nasal congestion and discharge in patients with allergic rhinitis. Methods Forty-eight patients with symptoms of allergic rhinitis were treated with the KTP/532 laser. All had positive skin tests for common allergens. Treatments were provided on an ambulatory basis in one to three sessions under local anesthesia with lidocaine nose spray. Outcome was determined by daily symptom reports and regular endoscopy examination and interviews for 12 months. Results Treatment was very well tolerated. There were no major side effects. At examination after 1 year, nasal obstruction was improved in 69% and nasal discharge in 40% of cases. Conclusion The KTP/532 YAG laser is effective for the treatment of nasal obstruction and discharge. Comparison with other techniques showed it to be the most effective in reducing nasal discharge. It can be done as an office procedure and does not damage the nasal mucous membrane. The KTP/532 YAG laser is effective as an additional treatment for patients refractory to medication.

scholarly journals The modern view of treatment of allergic rhinitis and it’s combination with bronchial asthma

2021 ◽  
pp. 92-98
Author(s):  
D. S. Smirnov ◽  
O. M. Kurbacheva
Keyword(s):  
Allergic Rhinitis ◽  
Bronchial Asthma ◽  
Inflammatory Diseases ◽  
Nasal Congestion ◽  
Combined Therapy ◽  
Correct Diagnosis ◽  
Economic Problem ◽  
Atrophic Rhinitis ◽  
Significant Treatment ◽  
Adequate Treatment

In recent years, there has been a significant increase in the prevalence of diseases of the nose and paranasal sinuses. Inflammatory diseases of the mucous membrane nasal cavities (rhinitis) are most commonly characterized as a syndrome in which the patient experiences some combination of persistent nasal symptoms, including rhinorrhea, sneezing, nasal congestion, itching and burning in the nasal cavity. Among the chronic forms of rhinitis, allergic rhinitis occupies a large place along with vasomotor, infectious, hypertrophic, catarrhal and atrophic rhinitis. Allergic rhinitis is a significant social and medico-economic problem, since it significantly reduces the quality of life of patients and requires significant treatment costs. This nosology is found in the practice of doctors of all specialties, however, the correct diagnosis and the appointment of adequate therapy can take many months and years. Currently, the concept of “common airways” is widely discussed, which demonstrates the close relationship between allergic rhinitis and bronchial asthma and proves that the inflammatory response can be supported and enhanced by interrelated mechanisms. Therefore, patients with allergic rhinitis should be examined for the presence of bronchial asthma. In turn, patients with bronchial asthma need to diagnose allergic rhinitis, and treatment should be aimed at suppressing allergic inflammation in both the upper and lower respiratory tract. This article discusses modern diagnostic and therapeutic approaches to patients with these diseases, which make it possible to efficiently and timely identify allergic rhinitis and initiate appropriate adequate treatment. The article also discusses the feasibility of using combined therapy with levocetirizine and montelukast in the above nosologies.

scholarly journals The Effect of Combined Septal and Turbinate Injection of Botulinum Toxin Type A in Allergic Rhinitis

2020 ◽  
Author(s):  
Mostafa Ismail ◽  
Alaa Nabil ◽  
Mostafa Nasr ◽  
balegh abdel hak ◽  
Osama Awad ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Botulinum Toxin ◽  
Nasal Congestion ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Limited Effectiveness ◽  
Significant Difference ◽  
Before And After

Objectives: Allergic rhinitis ( AR) has been recently increasing in prevalence, and traditional treatment strategies sometimes show limited effectiveness for patients with intractable AR. Botulinum toxin type A (BTX-A) is among the increasingly used alternative treatment options. This study was conducted aiming at clinical assessment of the effect of combined septal and turbinate injection of BTX-A for management of uncontrolled AR. Design and setting: A single-arm pilot study enrolled 40 patients having moderate to severe uncontrolled AR were recruited in between October 2018 and August 2019. Each patient received 45 units of BTX-A injected in 3 fixed points of each side of the nose: inferior turbinate (15IU), middle turbinate (15IU) and nasal septum (15IU). All patients were evaluated in terms of nasal hypersecretions, congestion and sneezing with visual analogue scale prior to treatment and at weeks 1, 2, 4, 8 and 12 during the follow-up period. Results: Throughout the 12 weeks follow-up period, a significant difference in the degree of nasal hypersecretions could be identified before and after BTX-A injection. Sneezing differed significantly only in the first 4 weeks while nasal congestion did not differ significantly, before and after BTX-A injection. BTX-A was well tolerated by the patients, with no serious adverse or systemic effects. Conclusion: Combined septal and turbinate injection of BTX-A, in patients with uncontrolled AR, may be a long-lasting therapeutic option for the treatment of nasal hypersecretions, but not as effective as for sneezing and nasal congestion.

scholarly journals Perennial allergic rhinitis in children: efficiency and safety of using «Ergocetal»

2021 ◽  
pp. 12-16
Author(s):  
T.R. Umanets ◽  
◽  
V.F. Lapshyn ◽  
A.A. Rudnev ◽  
O.I. Pustovalova ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Nasal Mucosa ◽  
Nasal Congestion ◽  
School Age Children ◽  
Perennial Allergic Rhinitis ◽  
Good Tolerance ◽  
Ocular Symptoms ◽  
Positive Therapeutic Effect ◽  
High Adherence ◽  
Key Words Allergic Rhinitis

Purpose — to evaluate the efficacy and safety of levocetirizine («Ergocetal») in children with perennial allergic rhinitis (PAR). Materials and methods. 30 children aged 6–16 years with PAR were examined. All children were prescribed levocetirizine («Ergocetal») 5 mg in the form of tablets once a day for a month for the treatment of PAR. The criteria for the effectiveness of the treatment were: regression of the main nasal and ocular symptoms of PAR (rhinorrhea, nasal congestion, nasal itching, sneezing, itching and redness of the eyes) according to the visual analogue scale (VAS); dynamics of nasal eosinophilia in a smearst from the nasal mucosa. Results. The studies have shown that prescribe of levocetirizine «Ergocetal» in monotherapy for school-age children with mild and intermittent PAR had a positive therapeutic effect on nasal and ocular symptoms, as well as on the intensity of eosinophilic inflammation in the nasal mucosa. Established good tolerance and the absence of side effects of «Ergotal» in the examined children. Conclusions. Therapeutic efficacy, absence of adverse reactions, high adherence to treatment make it possible to recommend levocetirizine («Ergocetal») as monotherapy for mild and intermittent PAR in school children. The research was carried out in accordance with the principles of the Helsinki declaration. The study protocol was approved by the Local Ethics Committee of an participating institution. The informed consent of the patient was obtained for conducting the studies. No conflict of interest was declared by the authors. Key words: allergic rhinitis, treatment, levocetirizine.

Sign in / Sign up

Export Citation Format

Share Document